Latest from Huntsman Cancer Institute

Neeraj Agarwal, MD, discusses his preferred sequencing strategies for treating patients with kidney cancer, and ongoing immunotherapy research in the field.
Benjamin Maughan, MD, PharmD, instructor, Division of Medical Oncology, Huntsman Cancer Institute, discusses the combination of abiraterone acetate (Zytiga) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer.
Brock O’Neil, MD, assistant professor, Division of Urology, University of Utah School of Medicine, Huntsman Cancer Institute, discusses adjuvant therapy for patients with bladder cancer.
Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses recent FDA approvals in renal cell carcinoma.
Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the advantages and disadvantages of choosing docetaxel as a therapy for patients with mCRPC.
Neeraj Agarwal, MD, recaps the latest advancements in newly diagnosed RCC. 
Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses remaining questions in renal cell carcinoma.
A new study has provided yet more evidence that survivors of endometrial cancer should be closely monitored for cardiovascular disease.
Publication Bottom Border
Border Publication
x